argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

819.14 27.13 −3.21%
Market cap
$53.2B
P/E
29.6×
Fwd P/E
32.4×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 — 5 —

+8 more TTM periods

ROE
27.07% 0.00% 22.63% 0.00%
ROA
23.15% 0.00% 19.54% 0.00%
ROIC
20.71% 0.00% 17.19% 0.00%
Return on Tangible Assets
26.22% 0.00% 22.96% 0.00%
Average Days of Receivables
132.94 0.00 142.37 0.00
Free Cash Flow per Share
22.12 0.00 9.60 0.00
Free Cash Flow
1,378.46 — 588.50 —
Capital Expenditures
(236.98) — (251.29) —
Other line items
Cash ROIC
11.49% — 5.44% —
Accounts Receivable Turnover
4.10 0.00 3.94 0.00
Accounts Payable Turnover
0.53 0.00 0.54 0.00
Inventory Turnover
1.50 0.00 1.15 0.00
Average Days of Payables
1,053.96 0.00 1,026.16 0.00
Days of Inventory on Hand
258.10 0.00 383.90 0.00
Tax Rate
(0.02) (0.01) 0.01 0.59
Research and Development Expense of Revenue
31.00% 31.47% 32.11% 35.10%
Selling, General and Administrative Expense of Revenue
28.86% 30.42% 32.18% 33.18%
Share Based Compensation of Revenue
13.35% 0.00% 16.40% 0.00%
Interest Coverage
392.41 320.63 258.16 213.48
Operating CF/Net income
0.94 0.00 0.65 0.00
Depreciation/Fixed assets
1.45 — 1.40 —
Capex/Depreciation
(3.13) — (3.74) —
Revenue per Share
85.52 76.61 69.31 60.07
Operating CF per Share
25.92 0.00 13.70 0.00
Capex per Share
(3.80) 0.00 (4.10) 0.00
Capex to Sales
0.04 0.00 0.06 0.00

Fold the line items

Columns are period end dates